Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121 · View on ClinicalTrials.gov ↗
Study Summary
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
Conditions Studied
Interventions
- DRUG ADRX-0706
Study Locations (20)
Other
- Beijing University Third Hospital — Beijing
- Fujian Cancer Hospital — Fujian
- Sun Yat-sen University Cancer Center — Guangzhou
- Hunan Cancer hospital — Hunan
- Shandong Cancer Hospital — Jinan
- Shanghai East Hospital — Shanghai
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan
Michigan
- Karmanos Cancer Institute — Detroit
- Henry Ford Cancer — Detroit
- START Midwest — Grand Rapids
California
- USC Norris Comprehensive Cancer Center — Los Angeles
- UCLA — Los Angeles
Florida
- Comprehensive Hematology Oncology — St. Petersburg
- Moffitt Cancer Center — Tampa
Texas
- University of Texas MD Anderson Cancer Center — Houston
- START San Antonio — San Antonio
Ohio
- The Ohio State University Wexner Medical Center — Hilliard
Oklahoma
- Stephenson Cancer Center — Oklahoma City
Tennessee
- Sarah Cannon Cancer Network — Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2023-09-26 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06036121
The ClinicalTrials.gov registry entry for NCT06036121 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adcentrx Therapeutics, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention — of which ADRX-0706 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06036121 reports 20 study locations spanning 9 distinct geographic areas — top geographies include Other, Michigan, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06036121 about?
NCT06036121 is a clinical study titled "A Study of ADRX-0706 in Select Advanced Solid Tumors". The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
What is the current status of trial NCT06036121?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2023-09-26. Estimated completion is 2026-12.
What conditions does trial NCT06036121 study?
This clinical trial studies the following conditions: Cervical Cancer, Solid Tumors, Urothelial Cancer, Triple Negative Breast Cancer (TNBC). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06036121?
The interventions under investigation include: ADRX-0706 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06036121?
This trial is sponsored by Adcentrx Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06036121 being conducted?
This trial has 20 study locations across California, Florida, Michigan, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.